GeneralConnection.com ➔ Dictionary
Dictionary Search

achondroplasia

Synonyms

Noun

1. achondroplasty

2. osteosclerosis congenita, chondrodystrophy, genetic disease, genetic disorder, genetic abnormality, genetic defect, congenital disease, inherited disease, inherited disorder, hereditary disease, hereditary condition

Usage
A new oral treatment for achondroplasia in children - Nature
FDA accepts sNDA for vosoritide in children with achondroplasia - Contemporary Pediatrics
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia - PR Newswire
BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia - simplywall.st
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia - Yahoo Finance
Next generation approaches to achondroplasia care - Drug Discovery News
Homozygous Achondroplasia With Long-Term Survival: Growth Patterns, Medical Interventions, and Practice Implications - Wiley Online Library
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit - BioSpace
New trial shows oral therapy increases growth in children with achondroplasia - News-Medical
Finding the right team for achondroplasia: Jeremy’s story - Boston Children's Answers
Oral infigratinib boosts growth velocity in achondroplasia study - 2 Minute Medicine
Vosoritide Shows 13.6 cm Height Gain Over Eight Years in Achondroplasia - The Clinical Trial Vanguard
Oral Infigratinib Therapy in Children with Achondroplasia - The New England Journal of Medicine
Once-Weekly Navepegritide Safe and Efficacious for Achondroplasia, With Carlos Bacino, MD - HCP Live
Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling - Nature
Navepegritide Shows 5.84 cm/year Growth Velocity in Achondroplasia Trial - The Clinical Trial Vanguard
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - Yahoo Finance
FDA approves dwarfism drug - Nature
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug - BioSpace
Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial - HCP Live
Q&A: Rethinking Treatment Frequency & Long-Term Outcomes for Patients With Achondroplasia - Physician's Weekly
BioMarin seeks full approval for VOXZOGO - grafa.com
BioMarin Seeks Full Approval for VOXZOGO in Achondroplasia - Intellectia AI
Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial - HCP Live
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward - BioSpace
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting - PR Newswire
COACH trial: hGH accelerates CNP benefits in achondroplasia - The Clinical Trial Vanguard
FDA Approves Navepegritide for Children With Achondroplasia - Pharmacy Times
'New achondroplasia drugs may increase height by up to 20 cm' - koreabiomed.com
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
Oral medication boosts annualized height velocity for children with achondroplasia - Healio
COACH Trial Confirms Durable Benefits in Achondroplasia - The Clinical Trial Vanguard
The latest on navepegritide for children with achondroplasia, with Carlos Bacino, MD - Contemporary Pediatrics
Oral infigratinib linked to improved growth and proportionality in achondroplasia - Contemporary Pediatrics
New mouse model uncovers achondroplasia's cellular growth plate dysregulation - News-Medical
Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia - Contemporary Pediatrics
Navepegritide's bone-alignment effects hold through 2 years - Contemporary Pediatrics
BridgeBio drug for genetic cause of dwarfism succeeds in key study - STAT
Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children - BioSpace
Ascendis drug data show leg alignment kept improving through 2 years - Stock Titan
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 - Fierce Biotech
FDA pushes back decision on Ascendis' achondroplasia drug to February - FirstWord PHARMA
New treatment gives hope to children with achondroplasia - Loma Linda University
FDA Issues Historic Approval for Navepegritide in Achondroplasia - Contemporary Pediatrics
Once-Weekly Treatment Approved for Achondroplasia in Kids - MedPage Today
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
FDA Grants Accelerated Approval to Yuviwel for Achondroplasia - Endocrinology Advisor
BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia - marketscreener.com
BridgeBio Pharma to Present Additional Positive PROPEL 3 Data and Multiple Achondroplasia and ADH1 Studies at ICCBH 2026 - Quiver Quantitative
FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older - HCP Live
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Achondroplasia Awareness – sponsored content - MyWabashValley.com
Pregnancy and Delivery in a Woman With Achondroplasia: A Multidisciplinary Management Approach - Cureus
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication - BioSpace
First-of-its-kind trial boosts growth in children with rare disorders - Children's National
Beyond the Growth Chart: Key Facts for Families Navigating an Achondroplasia Diagnosis - The Coal Valley News
Oral FGFR1-3 Inhibitor Boosted Height Velocity in Common Genetic Growth Disorder - MedPage Today
Ascendis Pharma Receives FDA Approval for YUVIWEL®, First Once-Weekly Treatment for Achondroplasia in Children - Quiver Quantitative
Once-weekly agent boosts annualized growth velocity for children with achondroplasia - Healio
Camp Ellellbee Creates Space for Connection, Joy and Open Conversations About Skeletal Conditions - BioMarin Pharmaceutical
BridgeBio to present achondroplasia study data at congress - Investing.com
Here we grow: Chondrocytes’ behavior reveals novel targets for bone growth disorders - EurekAlert!
Here we grow: chondrocytes’ behavior reveals novel targets for bone growth disorders - Asia Research News |
Early initiation of therapy with vosoritide: case report. Description of the first Italian patient affected by achondroplasia treated with vosoritide before 2 years of age - Frontiers
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BioMarin’s Vosoritide Shows 2.33 cm/yr Growth Gain in Hypochondroplasia Trial - The Clinical Trial Vanguard
Achondroplasia: oral infigratinib increases annualized height velocity vs placebo - Vera Health
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
FDA accepts BioMarin's application for full app... - Pluang
Ascendis wins FDA approval for achondroplasia drug, waits on EU action - Endpoints News
Arvada boy with dwarfism thrives at school thanks to doctor who goes the extra mile - 9News
Drug Combo ‘Potentially Revolutionary’ for Achondroplasia - Medscape
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid - Fierce Pharma
New Data from Week 52 of the Ongoing COACH Trial Showed - GlobeNewswire
Novel Combination Improved Growth in Kids With Achondroplasia, Study Suggests - MedPage Today
US FDA clears four NMEs, including those for dermatitis, achondroplasia - BioWorld News
Human genetic disease - Autosomal Dominant, Inheritance, Genes - Encyclopedia Britannica
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PR Newswire
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial - The Manila Times
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop - MedPage Today
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data - Investing.com
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
FDA accepts BioMarin application for full VOXZOGO approval - Investing.com
BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com
Vosoritide Meets Primary Endpoint in Phase 3 Hypochondroplasia Trial, Prompting Planned sNDA Submission to FDA - BioPharm International
Ascendis Announces Extension of FDA Review Period for - GlobeNewswire
Tyra Biosciences initiates paediatric study for achondroplasia treatment - Clinical Trials Arena
BridgeBio to present achondroplasia study data at congress By Investing.com - Investing.com Nigeria
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - Yahoo Finance
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld News
Vosoritide data support planned FDA submission for hypochondroplasia - Contemporary Pediatrics
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older - BioSpace
Inside pharma’s race to deliver new treatments for dwarfism - Pharma Voice
Jake Birecki: Making Space of Strength, Sports and Self - BioMarin Pharmaceutical
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ribomic’s RBM-007 ready for phase III in achondroplasia - BioWorld News
Foreign Language Equivalents
Foreign Language Equivalents of 'achondroplasia'
Language Equivalent   Language Equivalent
French achondroplasie    Spanish
Misspellings - Typos
achondroplaasia,   ahondroplasia,   achindroplasia,   achondroplasiia,   achondroplasoa,   achonsroplasia,   achondropalsia,   ahcondroplasia,   achondrolpasia,   acjondroplasia,   achondroplaisa,   achondropkasia,   achondriplasia,   achondroplaia,   cahondroplasia,   achondrooplasia,   achondorplasia,   acohndroplasia,   achonroplasia,   achondrpolasia,   achonndroplasia,   achondeoplasia,   achondroplsaia,   achondrplasia,   achondroplasi,   achondroplasiaa,   achondrop;asia,   achomdroplasia,   achondtoplasia,   achondrroplasia,   achonrdoplasia,   achondro[lasia,   axhondroplasia,   achondroplasai,   achodnroplasia,   achondoplasia,   achondrolasia,   achondroplasis,   acgondroplasia,   achpndroplasia,   aachondroplasia,   achndroplasia,   achondroplsia,   achondroplasua,   achoondroplasia,   chondroplasia,   acchondroplasia,   achondropasia,   achonfroplasia,   achondropladia,   achondroplasa,   achondropplasia,   achnodroplasia,   achhondroplasia,   acondroplasia,   achobdroplasia,   avhondroplasia,   achondroplaaia,   achondropllasia,   achondroolasia,   achondrpplasia,   schondroplasia,   achondroplassia,   achondroplssia,   achodroplasia,   achonddroplasia
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z